Clinical use of long-acting antipsychotics for the treatment of bipolar disorder type I patients

Clinical use of long-acting antipsychotics for the treatment of bipolar disorder type I patients

Purpose: This study aims to determine the usage frequency of long-acting injectable antipsychotics among bipolar disorder type 1 patients who presented to the Dicle University Faculty of Medicine Psychiatry and Mental Health outpatient clinic, the clinical characteristics of these patients, and the...

Full description

Bibliographic Details
Main Authors:	Derya Gül Bilen, Abdullah Atlı, Betül Uyar
Format:	Article
Language:	English
Published:	Cukurova University 2022-06-01
Series:	Cukurova Medical Journal
Subjects:	antipsychotics bipolar disorder long-acting injectable antipsychotics long-acting long-acting injectable
Online Access:	https://dergipark.org.tr/tr/download/article-file/2314703

Similar Items

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
by: E. Yavuz, et al.
Published: (2022-06-01)

Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01)

Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison
by: Harlin M, et al.
Published: (2023-06-01)

Comment on “Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison” [Letter]
by: Rege B, et al.
Published: (2023-07-01)

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
by: Amy M. VandenBerg, PharmD, BCPP
Published: (2022-11-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021-09-01)

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
by: Christoph U. Correll, et al.
Published: (2022-01-01)

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study
by: Yao-Yu Lin, et al.
Published: (2023-06-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023-08-01)

Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania
by: Ana A. Miron, et al.
Published: (2022-07-01)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
by: Citrome L, et al.
Published: (2022-01-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics
by: Antonio Ventriglio, et al.
Published: (2019-01-01)

Aripirazole-Long Acting Injectable in Pregnant Women with Schizophrenia: A Case Series
by: B. Fernández-Abascal, et al.
Published: (2022-06-01)

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
by: Stephan Reymann, et al.
Published: (2022-03-01)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
by: P. Ifteni, et al.
Published: (2021-04-01)

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
by: Ma N, et al.
Published: (2023-09-01)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021-07-01)

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
by: Donica Janzen, et al.
Published: (2022-05-01)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
by: Caballero Joshua PharmD, BCPP, FCCP, et al.
Published: (2023-08-01)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
by: Chih-Sung Liang, et al.
Published: (2021-11-01)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021-09-01)

Effectiveness of oral versus long-acting antipsychotic treatment early-phase schizophrenia patients: an open-label randomized trial
by: I. Winter, et al.
Published: (2022-06-01)

Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice
by: L. Gutiérrez Rojas, et al.
Published: (2021-04-01)

Use of Antipsychotic Long-acting Injection in Ekbom Syndrome: A Case of Delusional Parasitosis
by: Elvan ÇİÇEKÇİ, et al.
Published: (2020-07-01)

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations
by: Yifei Liu, et al.
Published: (2023-05-01)

Paliperidone Palmitate: A Breakthrough Treatment for Schizophrenia? A Review on Patient Adherence Levels, Healthcare Resource Utilization and Costs
by: Bramante S, et al.
Published: (2023-03-01)

Medication and symptom severity in schizophrenia patients in COVID-19 pandemic: A cross-sectional study
by: Asli Kazgan, et al.
Published: (2021-09-01)

Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes
by: Juan José Fernández-Miranda, et al.
Published: (2024-01-01)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
by: Litman R, et al.
Published: (2023-01-01)

Employment status of patients with schizophrenia spectrum disorder treated with long acting injectable paliperidone palmitate: Real world mirror image study
by: M. Markovic
Published: (2022-06-01)

An 8-year longitudinal study of long-acting injectable (LAI) antipsychotics. Prescription trends and therapeutic drug monitoring to inform precision dosing
by: D. Piacentino, et al.
Published: (2022-06-01)

Benefits of Community-based Treatment for Patients with Schizophrenia: Based on Long-acting Injectable Antipsychotic Agents
by: Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice, LI Qian, SI Tianmei
Published: (2024-03-01)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021-01-01)

Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
by: Andrea L. Murphy, et al.
Published: (2023-02-01)

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
by: García-Carmona JA, et al.
Published: (2023-09-01)

Case report on antipsychotic induced catatonia in an incarcerated patient
by: Han Nguyen, et al.
Published: (2023-08-01)

A case of tardive dyskinesia with paliperidone palmitate
by: Philip Kumar Boyanapally, et al.
Published: (2015-01-01)

Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
by: Di Lorenzo R, et al.
Published: (2022-04-01)